Editas Medicine (EDIT) Profit After Tax (2015 - 2025)
Editas Medicine (EDIT) reported Profit After Tax of -$25.1 million for Q3 2025, up 59.58% year-over-year from -$15.7 million in Q3 2024, and up 52.82% quarter-over-quarter from -$53.2 million in Q2 2025.
Editas Medicine (EDIT) Profit After Tax (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of Profit After Tax data on file, last reported at -$25.1 million in Q3 2025.
- Profit After Tax for Q3 2025 came in at -$25.1 million, up 59.58% year-over-year; the trailing twelve-month figure through Sep 2025 was -$199.8 million (up 5.1% YoY), and the FY2024 annual result was -$237.1 million, down 54.74% from the prior year.
- Profit After Tax improved to -$25.1 million in Q3 2025 per EDIT's latest filing, from -$53.2 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$18.9 million in Q4 2023 and troughed at -$76.1 million in Q1 2025.
- A 5-year average of -$50.4 million and a median of -$53.2 million in 2025 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2021 and 2023: Profit After Tax sank 599.83% in 2021, then jumped 68.93% in 2023.
- A 5-year view of Profit After Tax shows it stood at -$41.4 million in 2021, then tumbled by 46.58% to -$60.7 million in 2022, then jumped by 68.93% to -$18.9 million in 2023, then slumped by 140.52% to -$45.4 million in 2024, then jumped by 44.67% to -$25.1 million in 2025.
- Business Quant data shows EDIT's Profit After Tax at -$25.1 million in Q3 2025, -$53.2 million in Q2 2025, and -$76.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -25.12 Mn |
| Jun 30, 2025 | -53.24 Mn |
| Mar 31, 2025 | -76.09 Mn |
| Dec 31, 2024 | -45.40 Mn |
| Sep 30, 2024 | -62.14 Mn |
| Jun 30, 2024 | -67.61 Mn |
| Mar 31, 2024 | -61.95 Mn |
| Dec 31, 2023 | -18.87 Mn |
| Sep 30, 2023 | -45.02 Mn |
| Jun 30, 2023 | -40.29 Mn |
| Mar 31, 2023 | -49.04 Mn |
| Dec 31, 2022 | -60.74 Mn |
| Sep 30, 2022 | -55.73 Mn |
| Jun 30, 2022 | -53.45 Mn |
| Mar 31, 2022 | -50.52 Mn |
| Dec 31, 2021 | -41.44 Mn |
| Sep 30, 2021 | -39.08 Mn |
| Jun 30, 2021 | -55.26 Mn |
| Mar 31, 2021 | -56.73 Mn |
| Dec 31, 2020 | -62.50 Mn |